Key Takeaways Esperion priced a 30M-share offering at $2.50, expecting $75M in gross proceeds.ESPR shares fell 17% as investors reacted to the discounted pricing of the new issue.Proceeds will fund Nexletol, Nexlizet expansion, pipeline work and general corporate needs.Esperion Therapeutics (ESPR) recently announced that it is floating a secondary issue of 30 million shares of its common stock to the public at an issue price of $2.50 per share. The company expects to raise approximately $75 million in gross ...

Key Takeaways Esperion reached a settlement with Dr. Reddy's over patents for Nexletol and Nexlizet.RDY agreed not to launch U.S. generics of the drugs before April 19, 2040, under the deal.The settlement resolves remaining disputes with RDY tied to Esperion's key bempedoic acid patent.Esperion Therapeutics (ESPR) announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories (RDY) related to patents for the marketed drugs, Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ...

ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories, Inc. and its affiliate Dr. Reddy’s Laboratories Ltd. (together, Dr. Reddy’s Laboratories). This agreement resolves the patent litigation brought by Esperion against Dr. Reddy’s Laboratories in response to Dr. Reddy’s Laboratories’ Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of each of NEXLETOL and N ...

Core Viewpoint - Arrowhead Pharmaceuticals, Inc. has filed a Complaint for Declaratory Judgment against Ionis Pharmaceuticals, Inc. to declare the invalidity of Ionis's U.S. Patent No. 9,593,333 and assert that Arrowhead's planned commercialization of investigational plozasiran does not infringe this patent [1] Company Summary - Arrowhead Pharmaceuticals is currently under FDA review for its investigational drug plozasiran [1] - The company intends to vigorously defend its position regarding the patent dispute with Ionis Pharmaceuticals [1] Industry Context - The legal action highlights ongoing patent disputes within the pharmaceutical industry, particularly concerning investigational drugs and their commercialization [1]

Financial Data and Key Metrics Changes - Vicor recorded product revenues, licensing income, and a patent litigation settlement for Q2 of $141 million, up 50.1% sequentially from $94 million in Q1 2025 and up 64.3% from $85.9 million in Q2 2024 [8] - The gross profit margin for Q2 was 65.3%, an increase of 1810 basis points from the prior quarter, primarily due to the patent litigation settlement [8] - Net income for Q2 totaled $41.2 million, with GAAP diluted income per share at 91 cents based on a fully diluted share count of 45,077,000 shares [9] Business Line Data and Key Metrics Changes - Advanced products revenue increased 1.2% sequentially to $60.6 million, while Brick Products revenue increased 4% sequentially to $35.5 million [8] - Advanced Products' share of total revenue decreased to 63.1% from 63.7% in Q1 2025, with Brick Products' share increasing to 36.9% [8] Market Data and Key Metrics Changes - Shipments to stocking distributors increased 18.9% sequentially but decreased 14.3% year over year [8] - Exports as a percentage of total revenue decreased to approximately 51.9% from 60.8% in the prior quarter [8] Company Strategy and Development Direction - The company is focused on its top 100 customers and enabling high-performance modular power delivery networks, showcasing next-generation products with significant advances in power and current density [14][15] - The Gen five vertical power delivery solution is expected to engage with hyperscalers and AI processor companies, with a market SAM for these solutions expected to exceed $5 billion by 2027 [16][17] - The automotive market is seen as a high growth opportunity, with ongoing audits and collaborations with tier one OEMs [18] Management's Comments on Operating Environment and Future Outlook - Management indicated that 2025 is a year of uncertainty and opportunity, with a wide range of possible outcomes for quarterly and annual results [11] - The company expects 2025 to be a record year for revenue, despite uncertainties around tariffs and licensing [58] Other Important Information - The company undertook share repurchases totaling approximately $17.5 million during the quarter, with around 200,000 shares repurchased [83] - The book-to-bill ratio came in below one due to order cancellations from customers in China and hesitancy around tariffs [13] Q&A Session Summary Question: Inquiry about the patent litigation settlement and its implications - Management confirmed that the approximate return from the ITC case includes the patent litigation settlement and extends through 2026 [21][23] Question: Book-to-bill ratio and future bookings trend - Management believes the hesitancy around tariffs is now behind them, and customers are adapting to the new expectations [26] Question: Cancellations in end markets - Cancellations were primarily from the industrial market in China, affecting both older and advanced products [30] Question: Future of royalty streams - Management is actively pursuing infringers and expects to see continued growth in licensing streams, although challenges remain [31][63] Question: Dynamics of the new license settlement - Management could not disclose specifics but indicated that there are no ongoing royalties from the recent settlement [36] Question: Automotive market engagement - The company is in the audit phase with several customers, indicating a long-term strategy to establish itself as a supplier in the automotive market [68] Question: Future product delivery timelines - Management confirmed that they are on target with the delivery timelines for the Gen five vertical power delivery solution [46] Question: Operating expenses outlook - Management indicated that operating expenses may fluctuate but are currently balanced with revenue [75]

Financial Data and Key Metrics Changes - Vicor recorded product revenues, licensing income, and a patent litigation settlement for Q2 of $141 million, up 50.1% sequentially from $94 million in Q1 2025 and up 64.3% from $85.9 million in Q2 2024 [7] - The gross profit margin for Q2 was 65.3%, an increase of 1810 basis points from the prior quarter, primarily due to the patent litigation settlement [7] - Net income for Q2 totaled $41.2 million, with GAAP diluted income per share at 91 cents based on a fully diluted share count of 45,077,000 shares [9] Business Line Data and Key Metrics Changes - Advanced products revenue increased 1.2% sequentially to $60.6 million, while Brick Products revenue increased 4% sequentially to $35.5 million [7] - Advanced Products' share of total revenue decreased to 63.1% from 63.7% in Q1 2025, with Brick Products' share increasing to 36.9% [7] Market Data and Key Metrics Changes - Shipments to stocking distributors increased 18.9% sequentially but decreased 14.3% year over year [7] - Exports as a percentage of total revenue decreased sequentially to approximately 51.9% from 60.8% in the prior quarter [7] Company Strategy and Development Direction - The company is focused on its top 100 customers and enabling high-performance modular power delivery networks, with next-generation products being sampled to lead customers across four target markets [14] - The strategy includes pursuing additional actions against companies infringing on its intellectual property while continuing to innovate and expand customer engagements [16][19] Management's Comments on Operating Environment and Future Outlook - Management indicated that 2025 is a year of uncertainty and opportunity, with a wide range of possible outcomes for quarterly and annual results [11] - The company expects 2025 to be a record year for revenue, despite uncertainties related to tariffs and market conditions [56][58] Other Important Information - The company reported a cash and cash equivalents total of $338.5 million in Q2, an increase of $42.4 million sequentially [10] - The one-year backlog decreased by 9.6% from the prior quarter, closing at $155.2 million [11] Q&A Session Summary Question: Clarification on the patent litigation settlement and its financial implications - The settlement amount is part of the expected return through 2026, which includes royalties from OEM and hyperscaler licenses [22][24] Question: Book to bill ratio and future bookings trends - Management believes the hesitancy around tariffs is now behind them, and they expect improvements in bookings moving forward [27] Question: Details on order cancellations and affected markets - Cancellations were primarily from the industrial market in China, affecting both older and advanced products [31] Question: Future royalty streams and licensing growth - The company is actively pursuing infringers and expects to see growth in royalty streams as they enforce existing licenses [32] Question: Dynamics of the new licensing settlement - The settlement does not include ongoing royalties, and the company is focused on enforcing its intellectual property rights [39] Question: Progress on Gen five vertical power delivery solutions - The company is on target with the delivery timeline for Gen five solutions to lead customers, with significant progress reported [46][48] Question: Expectations for operating expenses going forward - Operating expenses are expected to remain balanced, with potential lumpiness due to ongoing legal actions [77]

Core Insights - Esperion has entered into a settlement agreement with Accord Healthcare Inc. to resolve patent litigation regarding the generic version of NEXLETOL, preventing Accord from marketing it in the U.S. before April 19, 2040, under certain conditions [1] - Ongoing patent litigation against other defendants related to NEXLETOL and NEXLIZET continues, with no assurance on the outcome regarding the marketing of generics before the same date [2] Company Overview - Esperion Therapeutics is a biopharmaceutical company focused on developing and commercializing FDA-approved oral, once-daily, non-statin medications for patients at risk of cardiovascular disease with elevated LDL-C levels, supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients [3] - The company is advancing its pre-clinical pipeline and developing next-generation ATP citrate lyase inhibitors (ACLYi) to create highly potent and specific inhibitors [3][4]

Core Insights - Esperion has entered into a settlement agreement with Micro Labs USA, resolving patent litigation related to the generic version of NEXLETOL, preventing Micro Labs from marketing it in the U.S. before April 19, 2040, unless specific circumstances arise [1] - Ongoing patent litigation against other defendants regarding NEXLETOL and NEXLIZET continues, with no assurance of a generic version being marketed before the same date [2] Company Overview - Esperion Therapeutics is a commercial stage biopharmaceutical company focused on developing and marketing new medicines for patients at risk of cardiovascular disease, specifically offering FDA-approved oral, once-daily, non-statin medications for elevated LDL-C [3] - The company is advancing its pre-clinical pipeline and aims to evolve into a leading global biopharmaceutical entity through commercial execution and international partnerships [4]

MORRISVILLE, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that United Therapeutics Corporation (UTHR) filed a complaint on May 9, 2025, in the U.S. District Court for the Middle District of North Carolina (Case No. 1:25-cv-00368) against Liquidia alleging infringement of U.S. Patent No. 11,357,782 (the '782 patent). Additionally, the complaint seeks to en ...